Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Assets (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Non-Current Assets readings, the most recent being $60.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 37.13% year-over-year to $60.4 million, compared with a TTM value of $273.8 million through Dec 2025, up 19.53%, and an annual FY2025 reading of $60.4 million, down 37.13% over the prior year.
  • Non-Current Assets hit $60.4 million in Q4 2025 for Apellis Pharmaceuticals, down from $68.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $96.1 million in Q4 2024, with the low at $20.5 million in Q1 2024.
  • Median Non-Current Assets over the past 5 years was $43.5 million (2022), compared with a mean of $47.5 million.
  • The sharpest move saw Non-Current Assets crashed 47.63% in 2023, then surged 329.02% in 2024.
  • Year by year, Non-Current Assets stood at $57.7 million in 2021, then fell by 29.5% to $40.7 million in 2022, then tumbled by 44.96% to $22.4 million in 2023, then skyrocketed by 329.02% to $96.1 million in 2024, then crashed by 37.13% to $60.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $60.4 million, $68.0 million, and $65.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.